Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
Firefly Neuroscience (NASDAQ: AIFF) has formed a strategic partnership with Neurology Consultants of Dallas (NCD) to enhance early detection and management of cognitive disorders. NCD will integrate Firefly's Brain Network Analytics (BNA) technology into its patient protocols and conduct clinical studies to identify biomarkers for predicting dementia onset. This collaboration aims to optimize patient care pathways and improve outcomes for those suffering from cognitive decline.
The partnership highlights the clinical value of BNA technology in providing diagnostic insights and trending analysis for conditions such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. By establishing cognitive baselines, healthcare providers can more accurately track changes and promote early detection. This integration is expected to enhance neurology testing for millions of U.S. patients by encouraging widespread adoption of advanced diagnostic tools.
Firefly Neuroscience (NASDAQ: AIFF) ha stretto una partnership strategica con Neurology Consultants of Dallas (NCD) per migliorare la rilevazione precoce e la gestione dei disturbi cognitivi. NCD integrerà la tecnologia Brain Network Analytics (BNA) di Firefly nei suoi protocolli per i pazienti e condurrà studi clinici per identificare biomarcatori in grado di predire l'insorgenza della demenza. Questa collaborazione mira a ottimizzare i percorsi di cura per i pazienti e a migliorare i risultati per coloro che soffrono di declino cognitivo.
La partnership evidenzia il valore clinico della tecnologia BNA nel fornire approfondimenti diagnostici e analisi delle tendenze per condizioni come Alzheimer, Parkinson, epilessia e sclerosi multipla. Stabilendo linee fondamentali cognitive, i fornitori di servizi sanitari possono monitorare più accuratamente i cambiamenti e promuovere la rilevazione precoce. Questa integrazione dovrebbe migliorare i test neurologici per milioni di pazienti negli Stati Uniti incoraggiando l'adozione diffusa di strumenti diagnostici avanzati.
Firefly Neuroscience (NASDAQ: AIFF) ha formado una asociación estratégica con Neurology Consultants of Dallas (NCD) para mejorar la detección temprana y el manejo de los trastornos cognitivos. NCD integrará la tecnología de Análisis de Redes Cerebrales (BNA) de Firefly en sus protocolos para pacientes y llevará a cabo estudios clínicos para identificar biomarcadores que predigan la aparición de demencia. Esta colaboración tiene como objetivo optimizar los caminos de atención al paciente y mejorar los resultados para aquellos que sufren de declive cognitivo.
La asociación destaca el valor clínico de la tecnología BNA al proporcionar información diagnóstica y análisis de tendencias para condiciones como Alzheimer, Parkinson, epilepsia y esclerosis múltiple. Al establecer líneas base cognitivas, los proveedores de atención médica pueden rastrear con mayor precisión los cambios y fomentar la detección temprana. Se espera que esta integración mejore las pruebas neurológicas para millones de pacientes en EE.UU. al fomentar la adopción generalizada de herramientas diagnósticas avanzadas.
파이어플라이 신경과학(NASDAQ: AIFF)은 댈러스 신경학 컨설턴트(NCD)와 전략적 파트너십을 체결하여 인지 장애의 조기 발견 및 관리를 개선하기로 했습니다. NCD는 환자 프로토콜에 파이어플라이의 브레인 네트워크 분석(BNA) 기술을 통합하고 치매 발병 예측을 위한 바이오마커를 식별하는 임상 연구를 수행할 것입니다. 이 협력은 환자 치료 경로를 최적화하고 인지 기능 저하로 고통받는 사람들의 결과를 개선하는 것을 목표로 하고 있습니다.
파트너십은 알츠하이머, 파킨슨병, 간질, 다발성 경화증과 같은 질환에 대해 진단 통찰력과 동향 분석을 제공하는 BNA 기술의 임상 가치를 강조합니다. 인지 기준선을 설정함으로써 의료 제공자는 변화 추적을 보다 정확하게 수행하고 조기 발견을 촉진할 수 있습니다. 이 통합은 진보된 진단 도구의 광범위한 채택을 촉진하여 미국의 수백만 환자에 대한 신경학적 테스트를 개선할 것으로 예상됩니다.
Firefly Neuroscience (NASDAQ: AIFF) a établi un partenariat stratégique avec Neurology Consultants of Dallas (NCD) pour améliorer la détection précoce et la gestion des troubles cognitifs. NCD intégrera la technologie Brain Network Analytics (BNA) de Firefly dans ses protocoles patients et réalisera des études cliniques pour identifier des biomarqueurs permettant de prédire l'apparition de la démence. Cette collaboration vise à optimiser les parcours de soins des patients et à améliorer les résultats pour les personnes souffrant de déclin cognitif.
Ce partenariat souligne la valeur clinique de la technologie BNA pour fournir des informations diagnostiques et des analyses de tendances sur des conditions telles qu'Alzheimer, Parkinson, épilepsie et sclérose en plaques. En établissant des lignes de base cognitives, les prestataires de soins peuvent suivre plus précisément les changements et favoriser la détection précoce. Cette intégration devrait améliorer les tests neurologiques pour des millions de patients américains en encourageant l'adoption généralisée d'outils de diagnostic avancés.
Firefly Neuroscience (NASDAQ: AIFF) hat eine strategische Partnerschaft mit Neurology Consultants of Dallas (NCD) gebildet, um die frühzeitige Erkennung und das Management von kognitiven Störungen zu verbessern. NCD wird die Brain Network Analytics (BNA) Technologie von Firefly in seine Patientenprotokolle integrieren und klinische Studien durchführen, um Biomarker zur Vorhersage des Auftretens von Demenz zu identifizieren. Diese Zusammenarbeit zielt darauf ab, die Patientenversorgung zu optimieren und die Ergebnisse für Menschen mit kognitiven Rückgängen zu verbessern.
Die Partnerschaft hebt den klinischen Wert der BNA-Technologie hervor, die diagnostische Einblicke und Trendanalysen für Erkrankungen wie Alzheimer, Parkinson, Epilepsie und Multiple Sklerose bietet. Durch die Etablierung kognitiver Referenzwerte können Gesundheitsdienstleister Veränderungen genauer verfolgen und die frühzeitige Erkennung fördern. Diese Integration wird voraussichtlich die neurologischen Tests für Millionen von Patienten in den USA verbessern, indem eine weitreichende Einführung fortschrittlicher diagnostischer Werkzeuge gefördert wird.
- Strategic partnership with Neurology Consultants of Dallas to enhance early detection and management of cognitive disorders
- Integration of Firefly's BNA technology into NCD's patient protocols
- Potential for improved patient outcomes and optimized care pathways
- Enhanced neurology testing capabilities for millions of U.S. patients
- Alignment with NCD's participation in the Centers for Medicare and Medicaid Services' GUIDE Model for dementia care
- None.
Insights
This partnership between Firefly Neuroscience and NCD marks a significant step in improving cognitive disorder management. The integration of Firefly's Brain Network Analytics (BNA) technology into NCD's protocols could potentially revolutionize early detection and treatment of conditions like Alzheimer's, Parkinson's and epilepsy.
The ability to establish cognitive baselines and track changes over time is particularly promising. This could lead to earlier interventions and more personalized treatment plans, potentially slowing disease progression. However, it's important to note that while this technology shows promise, its real-world efficacy in improving patient outcomes remains to be seen through rigorous clinical studies.
The partnership's alignment with the CMS GUIDE Model for dementia care further underscores its potential impact on healthcare quality and cost-effectiveness. If successful, this approach could set a new standard in neurology testing and cognitive health management.
Firefly's BNA technology represents a cutting-edge application of AI in healthcare. By incorporating this technology into clinical practice, NCD is positioning itself at the forefront of neurological care. The potential to identify biomarkers for predicting dementia onset is particularly exciting from a technological standpoint.
However, it's important to consider the challenges of implementing such advanced technology in a clinical setting. Issues like data privacy, algorithm transparency and integration with existing systems will need to be carefully addressed. Additionally, the success of this partnership will largely depend on the accuracy and reliability of Firefly's AI models in real-world scenarios.
If proven effective, this collaboration could accelerate the adoption of AI-driven diagnostic tools in neurology, potentially leading to more precise and timely interventions for millions of patients.
This strategic partnership could significantly boost Firefly Neuroscience's market position and revenue potential. The collaboration with a respected institution like NCD lends credibility to Firefly's technology and could accelerate its adoption in the healthcare sector. However, investors should note that the financial impact may not be immediate, as clinical studies and integration processes take time.
The alignment with the CMS GUIDE Model is particularly noteworthy, as it could potentially open doors to government contracts and reimbursement opportunities. This could lead to a steady revenue stream if the technology proves effective in improving dementia care outcomes.
While this news is positive for Firefly, it's important to consider the competitive landscape and potential regulatory hurdles in the AI healthcare space. Investors should monitor the progress of clinical studies and any regulatory developments that could impact the widespread adoption of this technology.
NCD Will Integrate Firefly’s BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes
TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced that it has formed a strategic partnership with the Neurology Consultants of Dallas (“NCD”) to help enhance early detection efforts and disease management for patients suffering from cognitive decline. NCD will incorporate Firefly’s Brain Network Analytics (“BNA”) technology into its patient workflow and conduct clinical studies aimed at identifying biomarkers for predicting the onset of dementia that can potentially optimize patient care pathways.
"NCD has been at the forefront of neurological care since the 1970s, providing inpatient and outpatient services. Its expertise and dedication to improving patient outcomes makes NCD an ideal partner for Firefly,” said Jon Olsen, Firefly’s CEO. "We look forward to continuing to update our BNA technology with real patient use cases and feedback to better serve those suffering from cognitive decline and other neurological disorders across the U.S."
"Our integration of Firefly's BNA technology highlights the clinical value of the platform, providing diagnostic insights and trending analysis of cognitive health in conditions such as Alzheimer's disease, Parkinson’s disease, epilepsy, multiple sclerosis, concussions, and general aging," added Dr. Puneet Gupta, NCD's VP Health Innovation Strategy and Ventures. "Incorporating BNA into our serial cognitive exams allows for a more comprehensive understanding of patients' brain function and cognitive health over time."
By establishing a baseline for every patient, healthcare providers can more accurately track cognitive changes, which will promote the early detection and effective management of cognitive decline. The integration of BNA technology is expected to enhance neurology testing for millions of patients in the U.S. by encouraging widespread adoption of advanced diagnostic tools.
Dr. Anna Tseng, NCD’s Chief Development Officer, concluded, “Recently, NCD was selected to participate in the Centers for Medicare and Medicaid Services’ GUIDE Model, which aims to significantly improve quality of life for people with dementia. We believe that our partnership with Firefly will enhance our ability to stage the level of cognitive impairment in patients participating in the program, and thereby manage their care accordingly by the stage of dementia. This aligns with our ongoing commitment to advancing patient care through innovative technology.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA) platform revolutionizes diagnostic and treatment methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has invested approximately
The BNA platform is a software as a medical solution (SAMS) that was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. The BNA platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition). These insights can enhance a clinician’s ability to accurately diagnose mental illnesses and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
About NCD
Neurology Consultants of Dallas (NCD), a distinguished physician-owned and physician-led practice, is dedicated to providing exceptional neurological care to the community. With a focus on treating the whole person, not just their condition, NCD offers leading-edge services for both adult and pediatric patients, inpatient and outpatient. Their team of board-certified and fellowship-trained neurologists are leaders in their field, sought out by their peers for complex cases and trusted by fellow physicians for their own families. They believe in a holistic approach, combining the latest research and technology with compassionate, individualized care.
NCD's comprehensive services include expertise across specialties, advanced diagnostics and imaging, clinical research, and neurorehabilitation. Their clinic’s state-of-the-art Neuro Testing Center offers overnight monitored EEG, epilepsy, and sleep evaluations. NCD recognizes that elevating patient care extends beyond the walls of their clinic. They actively collaborate with startups and established healthcare companies to refine products, shape future therapies, and optimize workflows, driving innovation that impacts healthcare on a broader scale.
Their commitment to excellence and patient-centered care sets them apart, making NCD the premier choice for neurological care in their community.
Forward-Looking Statements
Certain statements in this press release and the information incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and expenses associated with the Merger and other events and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the business combination; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
(212) 896-1254
Firefly@KCSA.com
Media Contact
KCSA Strategic Communications
Raquel Cona, Vice President
(516) 779-2630
Rcona@KCSA.com
FAQ
What is the purpose of Firefly Neuroscience's partnership with Neurology Consultants of Dallas?
How will Firefly's BNA technology be used in the partnership with NCD?
What is the potential impact of the Firefly Neuroscience (AIFF) and NCD partnership on patient care?
How does the Firefly Neuroscience (AIFF) partnership align with NCD's involvement in the GUIDE Model?
